Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-month open-label extension study of NPSP558 in adults with hypoparathyroidism
2011-001265-40Phase 3Completed
- Sponsor
- NPS Pharmaceuticals, Inc.
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of parathyroid hormone 1-84 in hypoparathyroidism, sponsored by NPS Pharmaceuticals, Inc. Primary endpoint: Composite biochemical/treatment response at Week 24. Started May 2011; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on 2011-001265-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001265-40.